T1	PrimaryOutcome 40 187	timing to achieve viral RNA negative conversion for SARS-CoV-2 in all three specimens, including nasopharyngeal swabs, throat swabs and stool swabs
T3	SecondaryOutcome 365 412	timing when CT imaging improvement was observed
T4	OutcomeDefinition 444 481	size and density reduction of lesions
R2	DefinedAs Arg1:T3 Arg2:T4	
T2	OtherOutcome 504 535	adverse events during treatment
T5	OtherOutcome 537 558	severe adverse events
T6	OtherOutcome 564 603	premature discontinuation of treatment.
T7	OutcomeDefinition 624 724	classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events
R1	DefinedAs Arg1:T2 Arg2:T7	
